Q1 Earnings Forecast for KNSA Issued By Wedbush

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) - Investment analysts at Wedbush issued their Q1 2026 earnings estimates for shares of Kiniksa Pharmaceuticals in a research note issued to investors on Tuesday, April 29th. Wedbush analyst D. Nierengarten anticipates that the company will post earnings per share of $0.31 for the quarter. Wedbush currently has a "Outperform" rating and a $34.00 target price on the stock. The consensus estimate for Kiniksa Pharmaceuticals' current full-year earnings is ($0.55) per share. Wedbush also issued estimates for Kiniksa Pharmaceuticals' Q2 2026 earnings at $0.35 EPS, Q3 2026 earnings at $0.39 EPS and Q4 2026 earnings at $0.42 EPS.

Kiniksa Pharmaceuticals (NASDAQ:KNSA - Get Free Report) last issued its quarterly earnings results on Tuesday, April 29th. The company reported $0.11 EPS for the quarter, beating analysts' consensus estimates of $0.02 by $0.09. Kiniksa Pharmaceuticals had a negative return on equity of 7.31% and a negative net margin of 2.36%. The firm had revenue of $137.79 million for the quarter, compared to analysts' expectations of $128.35 million. During the same quarter in the prior year, the firm earned ($0.25) EPS. The business's revenue for the quarter was up 72.5% compared to the same quarter last year.

KNSA has been the topic of a number of other reports. Citigroup started coverage on shares of Kiniksa Pharmaceuticals in a research note on Thursday, March 13th. They set a "buy" rating and a $40.00 price target on the stock. Jefferies Financial Group raised their price target on Kiniksa Pharmaceuticals from $40.00 to $45.00 and gave the stock a "buy" rating in a report on Tuesday, April 29th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Kiniksa Pharmaceuticals presently has a consensus rating of "Buy" and a consensus target price of $38.80.

Kiniksa Pharmaceuticals Stock Performance

NASDAQ KNSA traded down $0.09 during trading on Thursday, hitting $27.65. 662,184 shares of the company's stock traded hands, compared to its average volume of 478,684. The stock has a market capitalization of $2.01 billion, a price-to-earnings ratio of -197.49 and a beta of 0.31. The business has a 50 day moving average of $21.77 and a 200-day moving average of $21.32. Kiniksa Pharmaceuticals has a 12-month low of $17.38 and a 12-month high of $28.15.

Institutional Investors Weigh In On Kiniksa Pharmaceuticals

Institutional investors have recently made changes to their positions in the business. GAMMA Investing LLC lifted its stake in Kiniksa Pharmaceuticals by 84.8% in the first quarter. GAMMA Investing LLC now owns 1,238 shares of the company's stock worth $27,000 after purchasing an additional 568 shares during the last quarter. Asset Management One Co. Ltd. bought a new stake in shares of Kiniksa Pharmaceuticals in the 1st quarter valued at about $41,000. Wealthquest Corp purchased a new stake in Kiniksa Pharmaceuticals during the 1st quarter valued at about $42,000. Lazard Asset Management LLC bought a new position in Kiniksa Pharmaceuticals during the 4th quarter worth approximately $61,000. Finally, KLP Kapitalforvaltning AS bought a new position in Kiniksa Pharmaceuticals during the 4th quarter worth approximately $158,000. Hedge funds and other institutional investors own 53.95% of the company's stock.

Insider Buying and Selling

In related news, insider Ross Moat sold 18,259 shares of the stock in a transaction on Monday, April 21st. The stock was sold at an average price of $20.29, for a total value of $370,475.11. Following the transaction, the insider now owns 9,415 shares of the company's stock, valued at $191,030.35. This represents a 65.98 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Mark Ragosa sold 21,254 shares of the stock in a transaction dated Wednesday, April 30th. The shares were sold at an average price of $26.95, for a total value of $572,795.30. Following the transaction, the chief financial officer now owns 27,009 shares in the company, valued at $727,892.55. This trade represents a 44.04 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 218,548 shares of company stock valued at $5,210,745. Company insiders own 54.57% of the company's stock.

Kiniksa Pharmaceuticals Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.